But perhaps I might add that PYCs Cell Penetrating Peptides and method of delivery of the active mRNA to replace the defective gene product are very efficient and well targeted. So, even if a competitor has a replacement mRNA their delivery system might not work as well, so higher doses might be needed. This increases risk of adverse effects. Another possibility is that their treatment might have a shorter half-life and thus require more frequent dosage. So there will be several factors to be weighed up before choosing the “best” treatment. All just IMO, sitting in warm sun in a huge rose garden. What pleasure! And knowing that perhaps we will find out about Cohort 4 tomorrow (or soon) makes it even better.
PYC Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)